Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.
about
Risk-reducing medication for primary breast cancer: a network meta-analysisDiabetes mellitus and metformin in hepatocellular carcinomaMetformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-AnalysisObesity and cancer: mechanistic insights from transdisciplinary studiesWhy does obesity promote cancer? Epidemiology, biology, and open questionsEpidemiology and Inherited Predisposition for Sporadic Pancreatic AdenocarcinomaMechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cellsMetformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysisCancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approachesDissecting the Dual Role of AMPK in Cancer: From Experimental to Human StudiesDose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer CellsMetformin Induces Cell Cycle Arrest, Reduced Proliferation, Wound Healing Impairment In Vivo and Is Associated to Clinical Outcomes in Diabetic Foot Ulcer PatientsMATE2 Expression Is Associated with Cancer Cell Response to MetforminUsing Large Diabetes Databases for Research.Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic reviewMeta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients.Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy.Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.Assessing the effect of treatment duration on the association between anti-diabetic medication and cancer riskMetformin use and lung cancer risk in patients with diabetes.Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapyMetformin use and risk of prostate cancer: results from the REDUCE study.Repurposing old drugs to chemoprevention: the case of metformin.Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic StudyDiabetes, Diabetes Treatment, and Risk of Thyroid Cancer.A retrospective study on the role of diabetes and metformin in colorectal cancer disease survivalHigh efficacy of intravesical treatment of metformin on bladder cancer in preclinical model.Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson.Metformin therapy associated with survival benefit in lung cancer patients with diabetesPrognostic value of glycated hemoglobin in colorectal cancer.Diabetes, diabetes treatment, and mammographic density in Danish Diet, Cancer, and Health cohort.Disease drivers of aging.Obesity and breast cancer: not only a risk factor of the disease.Expanding the therapeutic spectrum of metformin: from diabetes to cancer.Metformin: risk-benefit profile with a focus on cancer.Drug repurposing in oncology--patient and health systems opportunities.Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes.Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.
P2860
Q24185817-B7D7A7E1-A53A-41BD-AEE8-7A63282C8044Q26741205-0099D96C-8718-4887-A374-E9FC9DF78805Q26765139-9B20D15A-F410-4A33-B220-D5F0DC8E623DQ26786829-04232F31-2F6E-430C-975B-0A139BB7B986Q26797301-218341C0-3956-498C-9A44-0DB00549D93FQ26801418-65C60CAB-C634-42C0-BE5F-85CBA3969B96Q26827387-2B1F58B5-7C8C-48B3-9FE4-5D891D2E5081Q27853104-797ADAC1-4BFD-4EE4-9B7B-99EAB2B9E4C5Q28074225-E2EE654B-B8C9-4DB9-80E1-72292E5683CBQ28080472-CD9EBB0E-0C0C-4DAC-AEE2-11565443B884Q28081491-DA0EDB46-A15B-44F1-96F0-8B3E5FAAA682Q28542653-735A4911-8256-464C-8524-E94428347841Q28550674-0E5FD6F3-21A4-4EFA-9C57-02FD13F525AFQ28555000-46AFC458-F88C-4207-805B-12652736CB8AQ30251480-5467B9C6-CDBC-44D7-B602-7B170EE130FBQ33655236-AE0E6272-539D-4CF3-8947-2A30F6C9B0BAQ33672932-AFC77F7B-4A4E-4592-8AA8-A55627824ACCQ33756414-F734BC1F-7FC5-4998-AE45-5630FFA20CFFQ33921635-C21B0082-66D1-470C-92E3-4BC6710CB56AQ34334262-A3A4572B-A067-4F3B-9EE8-1BE22C9A0FFFQ34565654-1273535B-4295-4C3B-8EF3-EF462B948336Q35046673-539D5E4F-B17A-4F24-AA32-5F46640667B9Q35368220-6D506C11-3D31-4FC1-8C65-0B80B547F0C9Q36296255-D085AB71-1959-4CD7-8F9F-0A3F71946D28Q36679911-86424F1D-5CC3-4B81-81DD-AA334647B718Q36712191-50177E6F-98E6-47AE-B886-7E6FD1F32C8AQ36716002-AAE5D660-76AD-49E2-B562-0095DBAFEE03Q36807881-0FBC5378-8935-4288-82FD-07053FDEBB75Q36962520-743ECC7B-D047-4FDB-9D8B-CE718FF2A7CDQ37137953-23D472C6-E65E-4281-9990-5210FF4A6A92Q37376577-BCF362E0-9275-4F62-B8DE-1AD3E2CD35B9Q37483467-DCD3BB60-1DE1-45D7-BD28-52C51A750EDAQ37568800-F6D95B45-6EA7-4577-AF1D-100C5CCF84F2Q37730342-C626566E-CFFC-405A-8CC2-86A1DED0CCA2Q38436984-0DA71ADC-E273-4434-BCB7-E2D651D06258Q38558943-4C48550F-8561-4191-8413-6F842109AA29Q38584636-80B72713-6E5C-4B21-BB89-DF895FB08290Q38611707-24ACBB41-5DC7-4ED9-93BB-3AA4FBB1F9A0Q38645266-0A76BA8E-3A6D-4F77-9F9D-8DF195049054Q38651175-FD0436B0-C30C-49B7-AA8B-C93D82C08C9E
P2860
Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Metformin and cancer risk and ...... ccount biases and confounders.
@ast
Metformin and cancer risk and ...... ccount biases and confounders.
@en
Metformin and cancer risk and ...... ccount biases and confounders.
@nl
type
label
Metformin and cancer risk and ...... ccount biases and confounders.
@ast
Metformin and cancer risk and ...... ccount biases and confounders.
@en
Metformin and cancer risk and ...... ccount biases and confounders.
@nl
prefLabel
Metformin and cancer risk and ...... ccount biases and confounders.
@ast
Metformin and cancer risk and ...... ccount biases and confounders.
@en
Metformin and cancer risk and ...... ccount biases and confounders.
@nl
P2093
P2860
P50
P921
P1476
Metformin and cancer risk and ...... ccount biases and confounders.
@en
P2093
Andrea DeCensi
Barbara K Dunn
Brandy M Heckman-Stoddard
Leslie Ford
P2860
P304
P356
10.1158/1940-6207.CAPR-13-0424
P577
2014-07-01T00:00:00Z